表紙
市場調查報告書

Orexin第二型受體:開發平台分析

Orexin Receptor Type 2 - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 359825
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Orexin第二型受體:開發平台分析 Orexin Receptor Type 2 - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 83 Pages
簡介

本報告提供以Orexin第二型受體為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

Orexin第二型受體概要

治療藥的開發

Orexin第二型受體:開發中的產品 - 各開發階段

Orexin第二型受體:開發中的產品 - 治療範圍別

Orexin第二型受體:開發中的產品 - 各適應症

Orexin第二型受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Orexin第二型受體:企業開發中的產品

Orexin第二型受體:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Orexin第二型受體的治療藥開發企業

  • Actelion Ltd
  • Eisai
  • Evotec AG
  • Heptares Therapeutics Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG

藥物簡介

Orexin第二型受體:暫停中的計劃

Orexin第二型受體:開發中止的產品

Orexin第二型受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2367TDB

Summary:

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Orexin Receptor Type 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Dementia Associated With Alzheimer's Disease, Hypersomnia, Major Depressive Disorder, Opioid Induced Side Effects, Parkinson's Disease and Sleep Disorders.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
  • The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
  • Eisai Co Ltd
  • Idorsia Pharmaceutical Ltd
  • Inexia Ltd
  • Johnson & Johnson
  • Orexia Ltd
  • Takeda Pharmaceutical Co Ltd
  • Yangtze River Pharmaceutical Group
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
  • lemborexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nemorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OPN-021 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • seltorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • suvorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-925 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-994 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YNT-185 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YZJ-1139 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 21, 2020: Idorsia's insomnia drug daridorexant passes Phase III study
  • Jan 23, 2020: Eisai: Dayvigo (Lemborexant) approved for treatment of insomnia in Japan
  • Dec 27, 2019: Pivotal phase 3 study of DAYVIGO (lemborexant) for the treatment of insomnia disorder published in JAMA network open
  • Dec 23, 2019: U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for treatment of insomnia in adult patients
  • Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer's Disease (CTAD) conference
  • Dec 02, 2019: Eisai to present latest data on lemborexant at 12th Clinical Trials on Alzheimer's Disease Conference
  • Nov 22, 2019: A sleeping pill that doesn't make you sway: a new targeted insomnia treatment
  • Oct 24, 2019: Trial to test insomnia drug for alcohol use disorder
  • Oct 01, 2019: Minerva Neurosciences announces update on Seltorexant
  • Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
  • Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress
  • Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1
  • Sep 19, 2019: Eisai to present latest data on Lemborexant at World Sleep Congress
  • Jul 11, 2019: Latest data on Eisai's lemborexant to be presented at Alzheimer's Association International Conference (AAIC) 2019
  • Jun 24, 2019: Minerva Neurosciences announces achievement of primary and key secondary objectives in phase 2b clinical trial of Seltorexant (MIN-202) in Insomnia
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Eisai Co Ltd, H1 2020
  • Pipeline by Idorsia Pharmaceutical Ltd, H1 2020
  • Pipeline by Inexia Ltd, H1 2020
  • Pipeline by Johnson & Johnson, H1 2020
  • Pipeline by Orexia Ltd, H1 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Pipeline by Yangtze River Pharmaceutical Group, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020